Beyond Palliation: Survival Advantage of Definitive Primary Tumor Treatment in Oligometastatic Sarcoma
International Journal of Radiation Oncology*Biology*Physics · 2026-09 · 126 (1) · e148-e149
DOI: 10.1016/j.ijrobp.2026.06.980 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2026-09. Verfasst von Y. Han und 10 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Han, Y., Ho, T., Siontis, B., Robinson, S., Okuno, S., Lee, K., Haddock, M., Rose, P., Laack, N., Mutter, R., & Welliver, M. (2026). Beyond Palliation: Survival Advantage of Definitive Primary Tumor Treatment in Oligometastatic Sarcoma. International Journal of Radiation Oncology*Biology*Physics, 126(1), e148-e149. https://doi.org/10.1016/j.ijrobp.2026.06.980
Vancouver
Han Y, Ho T, Siontis B, Robinson S, Okuno S, Lee K, et al. Beyond Palliation: Survival Advantage of Definitive Primary Tumor Treatment in Oligometastatic Sarcoma. International Journal of Radiation Oncology*Biology*Physics. 2026;126(1):e148-e149. doi:10.1016/j.ijrobp.2026.06.980
BibTeX
@article{Han2026,
author = {Han, Y. and Ho, T. and Siontis, B.L. and Robinson, S.I. and Okuno, S. and Lee, K.N. and Haddock, M.G. and Rose, P.S. and Laack, N.N. and Mutter, R.W. and Welliver, M.},
title = {Beyond Palliation: Survival Advantage of Definitive Primary Tumor Treatment in Oligometastatic Sarcoma},
journal = {International Journal of Radiation Oncology*Biology*Physics},
year = {2026},
volume = {126},
number = {1},
pages = {e148--e149},
doi = {10.1016/j.ijrobp.2026.06.980}
}
EUVIMED